Gordon Rustin

25.8k total citations · 5 hit papers
245 papers, 16.0k citations indexed

About

Gordon Rustin is a scholar working on Reproductive Medicine, Surgery and Oncology. According to data from OpenAlex, Gordon Rustin has authored 245 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Reproductive Medicine, 95 papers in Surgery and 70 papers in Oncology. Recurrent topics in Gordon Rustin's work include Ovarian cancer diagnosis and treatment (117 papers), Testicular diseases and treatments (56 papers) and Gestational Trophoblastic Disease Studies (31 papers). Gordon Rustin is often cited by papers focused on Ovarian cancer diagnosis and treatment (117 papers), Testicular diseases and treatments (56 papers) and Gestational Trophoblastic Disease Studies (31 papers). Gordon Rustin collaborates with scholars based in United Kingdom, United States and Australia. Gordon Rustin's co-authors include E.S. Newlands, Richard H. J. Beǵent, Jonathan A. Ledermann, L. Holden, Anwar R. Padhani, K. D. Bagshawe, Michael Friedländer, Charlie Gourley, Ignace Vergote and Philipp Harter and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Gordon Rustin

245 papers receiving 15.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

2009 1.6k citations Anwar R. Padhani, Gordon Rustin et al. profile →
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

2004 519 citations Gordon Rustin et al. Journal of Clinical Oncology profile →
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gordon Rustin United Kingdom	67	5.3k	5.1k	4.0k	3.4k	2.5k	245	16.0k
Amit M. Oza Canada	72	10.8k 2.0×	7.0k 1.4×	7.4k 1.8×	2.6k 0.8×	710 0.3×	599	21.7k
Andrew Berchuck United States	73	5.8k 1.1×	6.9k 1.3×	8.1k 2.0×	1.6k 0.5×	934 0.4×	358	19.9k
Roman Rouzier France	61	5.6k 1.0×	4.2k 0.8×	2.5k 0.6×	3.7k 1.1×	1.3k 0.5×	484	16.8k
Ursula A. Matulonis United States	77	13.4k 2.5×	8.2k 1.6×	7.9k 2.0×	1.6k 0.5×	993 0.4×	443	23.1k
David G. Mutch United States	68	4.3k 0.8×	6.9k 1.3×	4.0k 1.0×	4.6k 1.3×	968 0.4×	449	19.1k
Gordon C. Jayson United Kingdom	56	4.1k 0.8×	4.1k 0.8×	4.7k 1.2×	2.2k 0.6×	2.5k 1.0×	257	14.0k
R. Kreienberg Germany	54	4.3k 0.8×	1.5k 0.3×	2.1k 0.5×	1.3k 0.4×	1.6k 0.6×	434	10.6k
David M. Gershenson United States	76	5.2k 1.0×	12.0k 2.3×	4.2k 1.0×	5.9k 1.7×	747 0.3×	406	21.6k
Gini F. Fleming United States	60	8.2k 1.5×	5.4k 1.0×	4.1k 1.0×	2.4k 0.7×	760 0.3×	334	16.6k
Karen H. Lu United States	72	6.8k 1.3×	8.3k 1.6×	7.4k 1.8×	2.1k 0.6×	541 0.2×	427	21.6k

Countries citing papers authored by Gordon Rustin

Since Specialization

Citations

This map shows the geographic impact of Gordon Rustin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Rustin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Rustin more than expected).

Fields of papers citing papers by Gordon Rustin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Rustin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Rustin. The network helps show where Gordon Rustin may publish in the future.

Co-authorship network of co-authors of Gordon Rustin

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Rustin. A scholar is included among the top collaborators of Gordon Rustin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Rustin. Gordon Rustin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shamash, Jonathan, Rizwan Syed, Shah‐Jalal Sarker, et al.. (2019). A phase II study of carboplatin AUC-10 guided by positron emission tomography–defined metabolic response in metastatic seminoma. European Journal of Cancer. 115. 128–135. 8 indexed citations

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. UCL Discovery (University College London). 1 indexed citations

Glasspool, Rosalind, Robert Brown, Martin Gore, et al.. (2014). A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer. 110(8). 1923–1929. 84 indexed citations

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations

Vergote, Ignace, Agustin A. García, John P. Micha, et al.. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. 31(32). 4060–4066. 34 indexed citations

Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations

Oliver, R. Timothy D., Graham M. Mead, Gordon Rustin, et al.. (2011). Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). Journal of Clinical Oncology. 29(8). 957–962. 178 indexed citations

Rustin, Gordon. (2011). Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Annals of Oncology. 22. viii45–viii48. 25 indexed citations

Shaked, Yuval, Terence Tang, Jill Woloszynek, et al.. (2009). Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. Cancer Research. 69(19). 7524–7528. 64 indexed citations

10.

Huddart, Robert, Michael O’Doherty, Anwar R. Padhani, et al.. (2007). ¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology. 25(21). 3090–3095. 68 indexed citations

11.

Gore, Martin, Amit M. Oza, Gordon Rustin, et al.. (2002). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European Journal of Cancer. 38(1). 57–63. 82 indexed citations

12.

Fosså, Sophie D., Sally Stenning, A. Gerl, et al.. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. British Journal of Cancer. 80(9). 1392–1399. 89 indexed citations

13.

Rustin, Gordon, Ann E. Nelstrop, Søren M. Bentzen, Martine Piccart, & K. Bertelsen. (1999). Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology. 10. S21–S27. 15 indexed citations

14.

Brock, C., E.S. Newlands, Stephen R. Wedge, et al.. (1998). Phase I trial of temozolomide using an extended continuous oral schedule.. PubMed. 58(19). 4363–7. 228 indexed citations

15.

Rustin, Gordon, et al.. (1997). Pseudo-Meigs' Syndrome Secondary to an Ovarian Germ Cell Tumor. Gynecologic Oncology. 66(3). 539–541. 15 indexed citations

16.

McHugh, Patrick, Shôn Lewis, Sarah Ford, et al.. (1995). The efficacy of audiotapes in promoting psychological well-being in cancer patients: a randomised, controlled trial. British Journal of Cancer. 71(2). 388–392. 88 indexed citations

17.

Ledermann, Jonathan A., L. Holden, ES Newlands, et al.. (1994). The long‐term outcome of patients who relapse after chemotherapy for non‐seminomatous germ cell tumours. British Journal of Urology. 74(2). 225–230. 7 indexed citations

18.

Rustin, Gordon, et al.. (1991). A Phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. Annals of Oncology. 2(8). 607–608. 6 indexed citations

19.

Sensky, Tom, Amy Gilbert, Richard H. J. Beǵent, et al.. (1989). Physicians' Perceptions of Anxiety and Depression among Their Outpatients: Relationships with Patients and Doctors' Satisfaction with Their Interviews. Journal of the Royal College of Physicians of London. 23(1). 33–38. 27 indexed citations

20.

Rustin, Gordon, et al.. (1984). Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours.. BMJ. 288(6411). 103–106. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact